NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a Healthcare company (Biotechnology) with a market capitalization of $107M. The Maz Rating grades it against the other companies in its sector.
NRx Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.45, NRx Pharmaceuticals, Inc. trades at 24.0x sales. Over the last twelve months it generated about $4M of revenue and a net loss of $24M. It runs a gross margin of 25.2%, an operating margin of -556.5% and a net margin of -458.5%. It shows return on equity of 247.8%, return on invested capital of 2380.2% and a free cash flow yield of -22.9%. On the balance sheet: a debt-to-equity ratio of -0.49 and a current ratio of 0.76. Over the past 52 weeks the share price ranged from $1.62 to $5.06, with a beta of 2.07.
NRx Pharmaceuticals, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.